Compare AbCellera Biologics Inc (ABCL) vs Figs Inc (FIGS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FIGS stock trades at $9.90, down 0.9% today, with a mixed technical picture showing a bearish moving average trend but oversold RSI levels. The company reported strong Q1 2026 earnings, beating estimates with 28% revenue growth and raised full-year guidance. Analyst consensus is a Buy with a $18.00 price target, implying significant upside, though valuation ratios like a P/E of 44.91 remain elevated.

The outlook is cautiously optimistic, driven by robust revenue growth, expanding margins, and global expansion. Key risks include cost pressures from tariffs and freight, competitive threats, and the stock's high valuation requiring sustained execution. Near-term performance hinges on Q2 2026 earnings delivery against a $0.07 EPS expectation.